Home / Market Reports / Medical Devices & Consumables / Global Recombinant Human Neuregulin Market Growth 2024-2030

Global Recombinant Human Neuregulin Market Growth 2024-2030

Global Recombinant Human Neuregulin Market Growth 2024-2030

Product Code:1237471

Published Date: Nov 12,2024

Pages: 124

Region: Global

Category: Medical Devices & Consumables

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US 

The global Recombinant Human Neuregulin market size is projected to grow from US$ 216 million in 2024 to US$ 293 million in 2030; it is expected to grow at a CAGR of 5.2% from 2024 to 2030.

Recombinant human neuregulin is a class of EGF-like signaling molecules, which are a class of paracrine, autocrine and paracrine signaling polypeptides that mediate a variety of cellular functions in neurons and non-neural systems, including survival, proliferation and differentiation. NRGs participate in cell-cell crosstalk and play an important role in the development, maintenance and repair of organs such as the nervous system, heart and breast.

United States market for Recombinant Human Neuregulin is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Recombinant Human Neuregulin is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Recombinant Human Neuregulin is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Recombinant Human Neuregulin players cover BPS Bioscience, R&D Systems, Inc., YEASEN, Sinobiological, InVitria, etc. In terms of revenue, the global two largest companies occupied for a share nearly 
 % in 2023.

LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human Neuregulin Industry Forecast” looks at past sales and reviews total world Recombinant Human Neuregulin sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant Human Neuregulin sales for 2024 through 2030. With Recombinant Human Neuregulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Neuregulin industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Neuregulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Neuregulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Neuregulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Neuregulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Neuregulin.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Neuregulin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Purity < 97%
    Purity ≥ 97%

Segmentation by Application:
    Laboratory
    University
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    BPS Bioscience
    R&D Systems, Inc.
    YEASEN
    Sinobiological
    InVitria
    Thermo Fisher Scientific Inc.
    Cell Guidance Systems LLC
    Abcam Limited
    ACROBiosystems
    Proteintech Group, Inc
    BioLegend, Inc

Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Neuregulin market?
What factors are driving Recombinant Human Neuregulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Neuregulin market opportunities vary by end market size?
How does Recombinant Human Neuregulin break out by Type, by Application?